BR112017008693A2 - célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. - Google Patents
célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição.Info
- Publication number
- BR112017008693A2 BR112017008693A2 BR112017008693-0A BR112017008693A BR112017008693A2 BR 112017008693 A2 BR112017008693 A2 BR 112017008693A2 BR 112017008693 A BR112017008693 A BR 112017008693A BR 112017008693 A2 BR112017008693 A2 BR 112017008693A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- modified
- methods
- generating
- condition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009172 cell transfer therapy Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 abstract 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 abstract 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
a presente invenção se refere às composições e métodos para gerar uma célula t modificada com um ácido nucleico capaz de infrarregular a expressão de gene endógeno selecionado a partir do grupo que consiste em cadeia ¿ de tcr, cadeia ß de tcr, beta-2 microglobulina, uma molécula hla, ctla-4, pd1, e fas e compreendendo adicionalmente um ácido nucleico codificando um receptor de célula t (tcr) modificado compreendendo afinidade para um antígeno de superfície em uma célula alvo ou um ácido nucleico eletroporado codificando um receptor antigênico quimérico (car). também são incluídos métodos e composições farmacêuticas compreendendo a célula t modificada para terapia adotiva e tratamento de uma condição, tal como uma doença autoimune.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462073651P | 2014-10-31 | 2014-10-31 | |
US62/073651 | 2014-10-31 | ||
PCT/US2015/055799 WO2016069283A1 (en) | 2014-10-31 | 2015-10-15 | Altering gene expression in cart cells and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017008693A2 true BR112017008693A2 (pt) | 2018-02-27 |
Family
ID=55858177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017008693-0A BR112017008693A2 (pt) | 2014-10-31 | 2015-10-15 | célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. |
Country Status (12)
Country | Link |
---|---|
US (6) | US11208661B2 (pt) |
EP (3) | EP3215166A4 (pt) |
JP (4) | JP6879910B2 (pt) |
KR (3) | KR102546296B1 (pt) |
CN (3) | CN107249606A (pt) |
AU (3) | AU2015339744B2 (pt) |
BR (1) | BR112017008693A2 (pt) |
CA (2) | CA2964948A1 (pt) |
EA (1) | EA201790953A1 (pt) |
HK (1) | HK1243332A1 (pt) |
MX (2) | MX2017005698A (pt) |
WO (2) | WO2016069283A1 (pt) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
DK3115457T3 (da) | 2014-03-05 | 2019-11-04 | Univ Kobe Nat Univ Corp | Fremgangsmåde til modificering af genomsekvens til specifikt at konvertere nukleinsyrebaser af målrettet dna-sekvens og molekylært kompleks til anvendelse i samme |
US11390921B2 (en) | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
EA201790953A1 (ru) | 2014-10-31 | 2017-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Изменение экспрессии гена в cart-клетках и их применения |
CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
CN115029362A (zh) | 2015-02-06 | 2022-09-09 | 新加坡国立大学 | 核酸、包含其的工程免疫细胞及其生产方法和用途 |
IL302341A (en) * | 2015-03-27 | 2023-06-01 | Harvard College | Modified T cells and methods for their preparation and use |
WO2016164356A1 (en) | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
AU2016261600B2 (en) | 2015-05-08 | 2021-09-23 | President And Fellows Of Harvard College | Universal donor stem cells and related methods |
CN108135938A (zh) | 2015-07-16 | 2018-06-08 | 耶达研究及发展有限公司 | 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途 |
EP3328399B1 (en) | 2015-07-31 | 2023-12-27 | Regents of the University of Minnesota | Modified cells and methods of therapy |
JP6929837B2 (ja) | 2015-10-05 | 2021-09-15 | プレシジョン バイオサイエンシズ,インク. | ヒトt細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
CN108601821B (zh) | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
CA3002827A1 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
CN108495932B (zh) | 2015-11-27 | 2022-08-09 | 国立大学法人神户大学 | 用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体 |
EP3384027A1 (en) * | 2015-12-04 | 2018-10-10 | Novartis AG | Compositions and methods for immunooncology |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
CN109844116A (zh) | 2016-07-05 | 2019-06-04 | 约翰霍普金斯大学 | 包括使用h1启动子对crispr指导rna的改进的组合物和方法 |
US20200069818A1 (en) * | 2016-07-05 | 2020-03-05 | The Johns Hopkins University | Crispr/cas9-based compositions and methods for treating cancer |
CN106191062B (zh) * | 2016-07-18 | 2019-06-14 | 广东华南疫苗股份有限公司 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
IL308426A (en) | 2016-08-03 | 2024-01-01 | Harvard College | Adenosine nuclear base editors and their uses |
CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN106399375A (zh) * | 2016-08-31 | 2017-02-15 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法 |
CN106480097A (zh) * | 2016-10-13 | 2017-03-08 | 南京凯地生物科技有限公司 | 利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用 |
EP3519433A1 (en) | 2016-10-03 | 2019-08-07 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
GB2605540B (en) | 2016-10-18 | 2022-12-21 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
JP6858266B2 (ja) * | 2016-11-07 | 2021-04-14 | ジェノヴィー エービーGenovie Ab | T細胞レセプター、t細胞抗原及びそれらの機能的相互作用の同定及び特徴決定のための遺伝子操作された多成分システム |
AU2017352591A1 (en) | 2016-11-07 | 2019-05-02 | Genovie Ab | A two-part device for T-cell receptor synthesis and stable genomic integration to TCR-presenting cells |
GB201622044D0 (en) * | 2016-12-22 | 2017-02-08 | Ucl Business Plc | T cell-targeted T cells |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11613574B2 (en) | 2017-01-10 | 2023-03-28 | The General Hospital Corporation | Methods and compositions relating to ex vivo culture and modulation of T cells |
JP2020513775A (ja) * | 2017-01-10 | 2020-05-21 | ザ ジェネラル ホスピタル コーポレイション | 修飾されたt細胞及びその使用方法 |
EP3571295A1 (en) * | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
SG11201908271WA (en) * | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
EP3634493A1 (en) | 2017-05-08 | 2020-04-15 | Precision BioSciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
BR112019023608A2 (pt) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
CA3067244A1 (en) * | 2017-06-12 | 2018-12-20 | Emory University | T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies |
EP3638317A4 (en) | 2017-06-15 | 2021-03-17 | The Regents of The University of California | TARGETED NONVIRAL DNA INSERTIONS |
AU2018288048A1 (en) * | 2017-06-20 | 2019-12-19 | Jiangsu Hengrui Medicine Co., Ltd. | Method for knocking out target gene in T cell in vitro and crRNA used in the method |
WO2018236909A1 (en) * | 2017-06-20 | 2018-12-27 | La Jolla Institute For Allergy And Immunology | T-MODIFIED LYMPHOCYTE RECEPTORS AND METHODS OF USE IN INFLAMMATORY RESPONMS MODULATION AND ATHEROSCLEROSIS TREATMENT |
EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
EP3645038A1 (en) | 2017-06-30 | 2020-05-06 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
SG11202000402PA (en) | 2017-08-10 | 2020-02-27 | Nat Univ Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
EP3676376A2 (en) | 2017-08-30 | 2020-07-08 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
CN109456943A (zh) * | 2017-09-06 | 2019-03-12 | 亘喜生物科技(上海)有限公司 | 通用型嵌合抗原受体t细胞制备技术 |
CN109468278A (zh) * | 2017-09-08 | 2019-03-15 | 科济生物医药(上海)有限公司 | 基因工程化的t细胞及应用 |
EP3686275A4 (en) * | 2017-09-18 | 2021-09-29 | Edigene Inc. | GENE EDITING LYMPHOCYTE T AND RELATED USE |
EP3684408A1 (en) | 2017-09-19 | 2020-07-29 | Massachusetts Institute of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
CN109517820B (zh) * | 2017-09-20 | 2021-09-24 | 北京宇繁生物科技有限公司 | 一种靶向HPK1的gRNA以及HPK1基因编辑方法 |
CN107630006B (zh) * | 2017-09-30 | 2020-09-11 | 山东兴瑞生物科技有限公司 | 一种制备tcr与hla双基因敲除的t细胞的方法 |
KR20200104284A (ko) | 2017-10-03 | 2020-09-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
CN111465989A (zh) | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | 使用热点进行的新抗原鉴别 |
EP3702454A4 (en) | 2017-10-10 | 2021-08-04 | Hiroshima University | METHOD FOR GENERATING ANTIGEN-SPECIFIC REGULATORY T-CELLS (TREG) WITH EFFECTOR T-CELL (TEFF) ANTIGEN RECEPTORS |
CN117820491A (zh) | 2017-10-10 | 2024-04-05 | 国立大学法人广岛大学 | 使用铂talen的t细胞受体的完全取代技术 |
KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
CN107759699A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd30抗原的转基因t细胞及其制备方法与应用 |
CN107759700A (zh) * | 2017-10-18 | 2018-03-06 | 银丰生物工程集团有限公司 | 靶向cd19抗原的转基因t细胞及其制备方法与应用 |
CN107827989A (zh) * | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
WO2019084552A1 (en) | 2017-10-27 | 2019-05-02 | The Regents Of The University Of California | TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS |
JP7397791B2 (ja) | 2017-10-30 | 2023-12-13 | パクト ファーマ インコーポレイテッド | 初代細胞の遺伝子編集 |
CN107916269B (zh) * | 2017-11-17 | 2020-12-11 | 山东兴瑞生物科技有限公司 | 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用 |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
WO2019106163A1 (en) * | 2017-12-01 | 2019-06-06 | Cellectis | Reprogramming of genetically engineered primary immune cells |
WO2019118508A1 (en) * | 2017-12-12 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting ny-eso-1 and methods of use thereof |
US20190175651A1 (en) * | 2017-12-13 | 2019-06-13 | Janssen Biotech, Inc. | Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression |
JP7372920B2 (ja) * | 2017-12-29 | 2023-11-01 | セレクティス | Car t細胞の作製を改良するための方法 |
CN108559760A (zh) * | 2018-01-09 | 2018-09-21 | 陕西师范大学 | 基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法 |
WO2019138354A1 (en) | 2018-01-12 | 2019-07-18 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
EP3765054A4 (en) * | 2018-01-19 | 2022-01-12 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T CELLS WITH CHIMERIC ANTIGEN RECEPTORS |
CN108103027B (zh) * | 2018-02-02 | 2021-12-24 | 中国医学科学院血液病医院(血液学研究所) | 高效率血细胞重编程同时实现基因编辑的方法 |
JP2021514658A (ja) | 2018-03-06 | 2021-06-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 前立腺特異的膜抗原carおよびその使用方法 |
WO2019191114A1 (en) | 2018-03-27 | 2019-10-03 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
WO2019186274A2 (en) | 2018-03-30 | 2019-10-03 | University Of Geneva | Micro rna expression constructs and uses thereof |
KR20200138334A (ko) | 2018-04-02 | 2020-12-09 | 팩트 파마, 인크. | 펩티드-MHC comPACT |
US20210017249A1 (en) | 2018-04-05 | 2021-01-21 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
KR20210020873A (ko) | 2018-04-05 | 2021-02-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법 |
MA52193A (fr) | 2018-04-05 | 2021-02-17 | Juno Therapeutics Inc | Récepteurs de lymphocytes t et cellules modifiées les exprimant |
US11786554B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
CN108490174B (zh) * | 2018-04-18 | 2022-06-24 | 上海尚珞生物医药科技有限公司 | 检测car-t细胞的方法及其应用 |
JP2021522820A (ja) | 2018-05-11 | 2021-09-02 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 癌を治療するための方法及び組成物 |
JP2021523745A (ja) | 2018-05-16 | 2021-09-09 | シンテゴ コーポレイション | ガイドrna設計および使用のための方法およびシステム |
CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
CN112805369A (zh) * | 2018-08-08 | 2021-05-14 | 南特生物公司 | 重组cd1限制性t细胞及方法 |
CN112739817A (zh) * | 2018-09-21 | 2021-04-30 | 佧珐药业有限公司 | 表达有嵌合受体的t细胞 |
US20210395774A1 (en) * | 2018-09-25 | 2021-12-23 | Microbial Chemistry Research Foundation | Novel virus vector and methods for producing and using same |
CN112771071A (zh) | 2018-09-28 | 2021-05-07 | 麻省理工学院 | 胶原蛋白定位的免疫调节分子及其方法 |
CN109295106B (zh) * | 2018-09-30 | 2020-07-24 | 北京鼎成肽源生物技术有限公司 | 一种hafft1细胞 |
MX2021004214A (es) * | 2018-10-16 | 2021-07-15 | Intellia Therapeutics Inc | Composiciones y metodos de inmunoterapia. |
US20210292429A1 (en) * | 2018-11-07 | 2021-09-23 | Crispr Therapeutics Ag | Anti-liv1 immune cell cancer therapy |
SG11202104631SA (en) * | 2018-11-07 | 2021-06-29 | Crispr Therapeutics Ag | Anti-ptk7 immune cell cancer therapy |
CN111788302A (zh) * | 2018-11-21 | 2020-10-16 | 南京北恒生物科技有限公司 | 修饰的t细胞及其用途 |
CN113412117A (zh) | 2018-12-12 | 2021-09-17 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
CN109722437B (zh) * | 2018-12-29 | 2020-01-07 | 广州百暨基因科技有限公司 | 一种通用型car-t细胞及其制备方法和用途 |
CN109652378B (zh) * | 2018-12-29 | 2020-04-24 | 广州百暨基因科技有限公司 | 一种功能增强的通用型car-t细胞及其制备方法和用途 |
EP3911735A4 (en) * | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
EP3911369A4 (en) | 2019-01-18 | 2022-11-16 | Orthobio Therapeutics, Inc. | EDITING GENES TO IMPROVE JOINT FUNCTION |
JP2022520230A (ja) | 2019-02-12 | 2022-03-29 | パクト ファーマ インコーポレイテッド | 抗原特異的t細胞の同定のための組成物と方法 |
CA3130754A1 (en) * | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
CN109913501B (zh) * | 2019-03-01 | 2022-08-16 | 华东师范大学 | 一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法 |
CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
CA3134102A1 (en) * | 2019-03-18 | 2020-09-24 | Ludwig Institute For Cancer Research Ltd | A2/ny-eso-1 specific t cell receptors and uses thereof |
MX2021011325A (es) | 2019-03-19 | 2022-01-06 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleotidos. |
WO2020191378A1 (en) * | 2019-03-21 | 2020-09-24 | Allogene Therapeutics, Inc. | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY |
EP4332115A2 (en) | 2019-04-03 | 2024-03-06 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
JP2022531185A (ja) | 2019-04-30 | 2022-07-06 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 遺伝子改変t細胞を標的化するcd19を使用するb細胞悪性病変の同種細胞療法 |
JP2022538974A (ja) | 2019-06-26 | 2022-09-07 | マサチューセッツ インスチテュート オブ テクノロジー | 免疫調節融合タンパク質-金属水酸化物錯体およびその方法 |
CN112430575B (zh) * | 2019-08-26 | 2024-01-19 | 深圳市菲鹏生物治疗股份有限公司 | 通用型car-t细胞及其制备方法、应用以及抗肿瘤药物 |
AU2020343516A1 (en) * | 2019-09-06 | 2022-03-10 | Crispr Therapeutics Ag | Genetically engineered T cells having improved persistence in culture |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
KR20220097985A (ko) * | 2019-11-13 | 2022-07-08 | 크리스퍼 테라퓨틱스 아게 | Car-t 세포의 제조 방법 |
EP4058560A1 (en) * | 2019-11-13 | 2022-09-21 | CRISPR Therapeutics AG | Manufacturing process for making t cells expressing chimeric antigen receptors |
JP2023502986A (ja) * | 2019-11-20 | 2023-01-26 | カルセリックス ピーティーワイ. リミテッド | 増強された機能を有する免疫細胞を提供する方法 |
WO2021108557A1 (en) * | 2019-11-27 | 2021-06-03 | Stitch Bio, Llc | Methods and compositions for inducing tumor cell death |
CN115003802A (zh) * | 2020-01-02 | 2022-09-02 | 宁波茂行生物医药科技有限公司 | 一种经修饰的免疫效应细胞及其制备方法 |
WO2021147891A1 (zh) * | 2020-01-21 | 2021-07-29 | 苏州克睿基因生物科技有限公司 | 一种经修饰的免疫效应细胞及其用途 |
WO2021150078A1 (ko) * | 2020-01-23 | 2021-07-29 | 주식회사 강스템바이오텍 | Off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물 |
CA3174332A1 (en) * | 2020-04-21 | 2021-10-28 | Jason PERERA | Tcr/bcr profiling |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート,インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
CN113684258A (zh) * | 2020-05-18 | 2021-11-23 | 上海赛比曼生物科技有限公司 | 用于检测鼠源tcr转基因拷贝数的试剂盒及方法 |
WO2021263211A2 (en) * | 2020-06-25 | 2021-12-30 | Houston Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法 |
WO2022012531A1 (zh) * | 2020-07-14 | 2022-01-20 | 苏州克睿基因生物科技有限公司 | 一种经修饰的免疫细胞的制备方法 |
BR112023000738A2 (pt) * | 2020-07-16 | 2023-03-21 | Orthobio Therapeutics Inc | Composições farmacêuticas, métodos para o tratamento ou prevenção de uma doença, tratar claudicação canina, tratar claudicação equina, inativar uma il-1a ou il-1ss endógena e reduzir a expressão do gene il-1a ou il-1ss, método de tratamento de um indivíduo com artrite, doença articular e osteoartrite, método mediado por crispr/cas9 para tratamento de doenças articulares, nuclease crisprcas, repetições palindrômicas, sistema vetorial e método de alteração de uma sequência de ácido nucleico |
CN112266899A (zh) * | 2020-10-26 | 2021-01-26 | 北京卡替医疗技术有限公司 | 修饰的免疫细胞及其用途 |
WO2022106731A1 (en) * | 2020-11-23 | 2022-05-27 | Ludwig-Maximilians-Universität München | Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof |
US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN112899227B (zh) * | 2021-01-14 | 2022-09-13 | 中国科学院微生物研究所 | 一种调控辅助性t细胞功能的方法 |
JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | T細胞療法およびdgk阻害剤の組合せ |
CN116964083A (zh) * | 2021-03-04 | 2023-10-27 | 艾洛基治疗公司 | 用于保护治疗性细胞免于发生同种异体排斥和激活诱导的细胞死亡的FasL表达和FasR基因敲除 |
WO2022192249A2 (en) * | 2021-03-08 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for assessing and treating t cell dysfunction |
CA3230927A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
WO2023055942A1 (en) * | 2021-09-29 | 2023-04-06 | The Johns Hopkins University | Methods and compositions to augment efficacy and reduce toxicity of non-engrafting, cd8-depleted allogenic donor lymphocyte infusions |
WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
CN113980907B (zh) * | 2021-12-24 | 2022-03-15 | 山东兴瑞生物科技有限公司 | 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用 |
CN114591963B (zh) * | 2022-05-10 | 2022-07-19 | 上海优替济生生物医药有限公司 | sgRNA及利用其构建GM-CSF(-)细胞的方法 |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA120409A (en) | 1909-05-13 | 1909-09-07 | Hiram Lucas Piper | Signal lamp |
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
US6080840A (en) | 1992-01-17 | 2000-06-27 | Slanetz; Alfred E. | Soluble T cell receptors |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
DK0663817T3 (da) | 1993-08-10 | 2000-03-13 | Gore & Ass | Celleindkapslingsindretning |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6143291A (en) * | 1995-05-04 | 2000-11-07 | Us Navy | Methods for modulating T cell survival by modulating bcl-XL protein level |
JPH10503964A (ja) | 1995-06-07 | 1998-04-14 | ゴア ハイブリッド テクノロジーズ,インコーポレイティド | 治療用デバイスのための移植可能な閉じ込め装置並びにその中にそのデバイスを装填及び再装填する方法 |
US5626561A (en) | 1995-06-07 | 1997-05-06 | Gore Hybrid Technologies, Inc. | Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
AU6854696A (en) | 1995-09-22 | 1997-04-09 | Gore Hybrid Technologies, Inc. | Improved cell encapsulation device |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
PT942968E (pt) | 1996-12-03 | 2008-03-27 | Amgen Fremont Inc | Anticorpos totalmente humanos que se ligam ao egfr |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
AU742045B2 (en) | 1997-04-14 | 2001-12-13 | Amgen Research (Munich) Gmbh | Novel method for the production of anti-human antigen receptors and uses thereof |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
ATE511400T1 (de) | 2000-03-03 | 2011-06-15 | Genetronics Inc | Nukleinsäure-fomulierungen zur genverabreichung |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
AU2004286198C1 (en) | 2003-08-18 | 2011-02-24 | Medimmune, Llc | Humanization of antibodies |
US20050042664A1 (en) | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
CA2566363C (en) | 2004-05-19 | 2014-12-16 | Avidex Ltd | High affinity ny-eso t cell receptor |
CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
KR20080086983A (ko) | 2005-12-07 | 2008-09-29 | 제네트로닉스, 인코포레이티드 | 가변 부피의 전기천공 챔버 및 이의 사용 방법 |
ES2382777T3 (es) * | 2006-05-03 | 2012-06-13 | Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services | Receptor de células T quimérico y materiales relacionados y métodos de uso |
WO2007150054A2 (en) * | 2006-06-24 | 2007-12-27 | Mrugesh Shah | Immunogenic compositions having altered glycosylations |
US8088379B2 (en) | 2006-09-26 | 2012-01-03 | The United States Of America As Represented By The Department Of Health And Human Services | Modified T cell receptors and related materials and methods |
WO2008037943A1 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | Cells transformed with nucleic acid encoding ny-eso t cell receptors |
HUE038506T2 (hu) | 2007-03-30 | 2018-10-29 | Memorial Sloan Kettering Cancer Center | Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon |
KR20100067089A (ko) * | 2007-08-30 | 2010-06-18 | 제넨테크, 인크. | T 세포를 조정하기 위한 방법 및 조성물 |
US8268620B2 (en) * | 2008-10-24 | 2012-09-18 | Wisconsin Alumni Research Foundation | OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells |
WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
TWI596211B (zh) | 2010-08-04 | 2017-08-21 | 幹細胞生物科技公司 | 體幹細胞 |
ME02810B (me) | 2010-09-20 | 2018-01-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t ćelijski receptori i t ćelijski epitopi |
CN108103085A (zh) | 2010-12-09 | 2018-06-01 | 宾夕法尼亚大学董事会 | 嵌合抗原受体-修饰的t细胞治疗癌症的用途 |
ES2888651T3 (es) | 2011-07-29 | 2022-01-05 | Univ Pennsylvania | Receptores de conmutación coestimulantes |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
JP2015513399A (ja) | 2012-02-22 | 2015-05-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌の治療のために有用なt細胞の存続的集団を作製するための組成物および方法 |
JP2015514421A (ja) * | 2012-04-17 | 2015-05-21 | ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォーコマーシャライゼーションThe University Of Washington Through Its Center For Commercialization | Hlaクラスiiタンパク質の発現能を有するhlaクラスii欠損細胞、hlaクラスi欠損細胞、及びその使用 |
EP2852613B1 (en) | 2012-05-22 | 2019-01-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Murine anti-ny-eso-1 t cell receptors |
LT3241902T (lt) | 2012-05-25 | 2018-06-25 | The Regents Of The University Of California | Būdai ir kompozicijos, skirti rnr nukreiptos tikslinės dnr modifikacijai ir rnr nukreiptos transkripcijos moduliacijai |
US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
SG11201407802WA (en) | 2012-05-25 | 2015-01-29 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
EP2872526B1 (en) | 2012-07-13 | 2020-04-01 | The Trustees of the University of Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
MX367730B (es) * | 2012-09-04 | 2019-09-04 | Cellectis | Receptor de antigeno quimerico multi-cadena y usos del mismo. |
EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
CN113005148A (zh) | 2013-01-16 | 2021-06-22 | 爱默蕾大学 | Cas9-核酸复合物及其相关用途 |
CN105283539A (zh) * | 2013-03-12 | 2016-01-27 | 桑格摩生物科学股份有限公司 | 用于hla的修饰的方法和组合物 |
WO2014160030A2 (en) | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen |
US9587237B2 (en) * | 2013-03-14 | 2017-03-07 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
US9937207B2 (en) * | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
DK2981607T3 (da) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
KR102220382B1 (ko) | 2013-05-13 | 2021-02-25 | 셀렉티스 | 면역요법을 위한 매우 활성인 t 세포를 조작하는 방법 |
US11311575B2 (en) * | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
EP2997146A4 (en) | 2013-05-15 | 2017-04-26 | Sangamo BioSciences, Inc. | Methods and compositions for treatment of a genetic condition |
AU2014273490B2 (en) * | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
HUE048558T2 (hu) * | 2014-03-11 | 2020-07-28 | Cellectis | Eljárás allogén transzplantációra kompatibilis T-sejtek létrehozására |
AU2015245469B2 (en) | 2014-04-11 | 2020-11-12 | Cellectis | Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment |
KR20230152175A (ko) | 2014-04-18 | 2023-11-02 | 에디타스 메디신, 인코포레이티드 | 암 면역요법을 위한 crispr-cas-관련 방법, 조성물 및 구성성분 |
US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
WO2016054086A1 (en) | 2014-09-30 | 2016-04-07 | The Regents Of The University Of California | Codon-optimized lentiviral vector for stem cell reprogramming |
EP3204399A4 (en) * | 2014-10-09 | 2018-04-25 | Seattle Children's Hospital, dba Seattle Children's Research Institute | Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid |
EA201790953A1 (ru) * | 2014-10-31 | 2017-10-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Изменение экспрессии гена в cart-клетках и их применения |
IL302341A (en) * | 2015-03-27 | 2023-06-01 | Harvard College | Modified T cells and methods for their preparation and use |
WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
-
2015
- 2015-10-15 EA EA201790953A patent/EA201790953A1/ru unknown
- 2015-10-15 MX MX2017005698A patent/MX2017005698A/es unknown
- 2015-10-15 WO PCT/US2015/055799 patent/WO2016069283A1/en active Application Filing
- 2015-10-15 CN CN201580071678.1A patent/CN107249606A/zh active Pending
- 2015-10-15 KR KR1020177014805A patent/KR102546296B1/ko active IP Right Grant
- 2015-10-15 US US15/516,052 patent/US11208661B2/en active Active
- 2015-10-15 CA CA2964948A patent/CA2964948A1/en active Pending
- 2015-10-15 CN CN202111354276.6A patent/CN114836385A/zh active Pending
- 2015-10-15 AU AU2015339744A patent/AU2015339744B2/en active Active
- 2015-10-15 KR KR1020237020503A patent/KR20230098910A/ko not_active Application Discontinuation
- 2015-10-15 WO PCT/US2015/055780 patent/WO2016069282A1/en active Application Filing
- 2015-10-15 EP EP15855440.2A patent/EP3215166A4/en active Pending
- 2015-10-15 EP EP23156585.4A patent/EP4219725A3/en active Pending
- 2015-10-15 BR BR112017008693-0A patent/BR112017008693A2/pt not_active Application Discontinuation
- 2015-10-15 JP JP2017523279A patent/JP6879910B2/ja active Active
- 2015-10-15 KR KR1020177014804A patent/KR20170075013A/ko not_active IP Right Cessation
- 2015-10-15 JP JP2017523296A patent/JP2018500006A/ja not_active Ceased
- 2015-10-15 EP EP15855146.5A patent/EP3215168B1/en active Active
- 2015-10-15 CN CN201580071634.9A patent/CN107206024B/zh active Active
- 2015-10-15 CA CA2964953A patent/CA2964953A1/en active Pending
- 2015-10-15 AU AU2015339743A patent/AU2015339743C1/en active Active
- 2015-10-15 US US15/516,240 patent/US20170335331A1/en not_active Abandoned
-
2017
- 2017-04-28 MX MX2023004169A patent/MX2023004169A/es unknown
-
2018
- 2018-02-27 HK HK18102825.7A patent/HK1243332A1/zh unknown
- 2018-04-25 US US15/962,379 patent/US11203758B2/en active Active
-
2020
- 2020-07-30 US US16/943,335 patent/US20200407728A1/en active Pending
- 2020-12-16 JP JP2020208069A patent/JP2021058196A/ja active Pending
-
2021
- 2021-01-11 AU AU2021200118A patent/AU2021200118B2/en active Active
- 2021-11-24 US US17/456,436 patent/US20220145306A1/en active Pending
- 2021-12-14 US US17/550,455 patent/US20220154190A1/en active Pending
-
2023
- 2023-01-16 JP JP2023004286A patent/JP2023037006A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017008693A2 (pt) | célula t modificada, métodos para gerar uma célula t modificada, para tratar uma doença ou condição, para estimular uma resposta imune mediada por célula t e para terapia de transferência de célula adotiva, uso de uma célula t modificada, e, composição. | |
PH12018500965A1 (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
AR125268A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
BR112018008442A2 (pt) | receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados | |
EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
BR112017018770A2 (pt) | redução da tolerância imunológica induzida por pd-l1 | |
BR112017006710A2 (pt) | vetor de expressão de car e células t expressando car | |
BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
BR112018067698A2 (pt) | células modificadas para imunoterapia | |
BR112017019914A2 (pt) | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b | |
BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
BR112017003104A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico anti-cd123 | |
EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
BR112016023513A2 (pt) | expressão de transgene relacionada com fármacos | |
BR112016016699A2 (pt) | Anticorpos humanos para pd-1 | |
BR112018008783A2 (pt) | terapia-alvo de câncer | |
BR112016013187A2 (pt) | receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos | |
EP4303229A3 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
BR122020002986A8 (pt) | Método e composições para imunoterapia celular | |
BR112017000939A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico de cll-1 | |
BR112015021819A2 (pt) | Tratamento de câncer utilizando receptor quimérico de antígeno humanizado anti-cd19 | |
BR112019021857A2 (pt) | Métodos e composições de célula t aperfeiçoada | |
BR112016028755A2 (pt) | anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo. | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |